Salute e Benessere

Press release: SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER…

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARESGhent, Belgium, 5 July 2024 – Sequana Medical NV(Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that in the context of (i) a subscription to new shares by certain non-executive independent directors pursuant to the "restricted share unit" or "RSU" plan as…
Nasdaq GlobeNewswire
05/07/2024

Global Contrast Media Injectors Market to Reach USD 2.3 billion by 2029 driven…

Browse in-depth TOC on "Contrast Media Injectors Market" Browse in-depth TOC on "Contrast Media Injectors Market" 180 - Tables50 - Figures206 - Pages Key Players in the Contrast Media Injectors Market: A Competitive Landscape The contrast media injectors market is consolidated, with key players adopting strategies such as partnerships, acquisitions, and expansions to maintain their market positions. As of 2023, the major players in this market include Bayer AG (...
PR Newswire
05/07/2024

RECOMMENDED CASH OFFER for MARIADB PLC by MERIDIAN BIDCO LLC an affiliate of K1…

MANHATTAN BEACH, Calif., July 5, 2024 /PRNewswire/ -- On 24 May 2024, Meridian Bidco LLC ("Bidco") made an offer to acquire the entire issued and to be issued share capital of MariaDB plc ("MariaDB") (the "Offer") with the terms and conditions of the Offer set out in the offer document despatched and filed by Bidco as Exhibit (a)(1)(A) to the Tender Offer Statement and Rule 13e-3 Transaction Statement filed on Schedule TO with the US Securities and Exchange…
PR Newswire
05/07/2024

IM Cannabis Announces Intention to Complete Consolidation

After giving effect to the Consolidation, the Common Shares will be reduced from 13,394,136 to 2,232,357 Common Shares. No fractional Common Shares will be issued in connection with the Consolidation. Instead, all fractional Common Shares equal to or greater than one-half resulting from the Consolidation will be rounded to the next whole number, otherwise, the fractional Common Share will be cancelled. The exercise price and/or conversion price and number of Common Shares issuable under any of…
PR Newswire
05/07/2024

Zhiyi Biotech Successfully Completes Phase I Clinical Trial of SK10 for the…

This promising result lays the foundation for SK10 as a potential novel drug for CID patients. This promising result lays the foundation for SK10 as a potential novel drug for CID patients. About SK10: SK10, the firstBacteroides fragilis -based LBP obtained FDA IND approval, is also the first LBP of Next-generation probiotics developed by Chinese biotech company that approved for clinical trials by FDA. Studies have shown that SK10 can ameliorate 5-FU induced injury via mitochondrial...
PR Newswire
05/07/2024

XIAOHONGSHU Shines at VOGUE Business Global Beauty Summit

The summit featured Chujing, Head of Personal Care Department at XIAOHONGSHU, alongside over 100 global brand executives and marketing specialists from prestigious international companies such as LVMH Beauty, Kering Beauty, Estée Lauder, L'Oréal, P&G, Unilever, and Coty. Together, they discussed strategies to tap into and leverage local markets in the face of global trends, sparking new inspirations in BPC solutions and driving the global growth of brands. The summit featured Chujing, Head…
PR Newswire
05/07/2024

MAGic™ BioProcessing Secures Patent in USA and China

MAGic™ BioProcessing remains committed to advancing the field of separation technology and delivering innovative solutions that address the evolving needs of bio manufacturing. With this patented technology, MAGic™ BioProcessing is poised to revolutionize separation processes, driving efficiency, and enabling new processes in biotechnology and beyond. MAGic™ BioProcessing remains committed to advancing the field of separation technology and delivering innovative solutions that address the...
PR Newswire
05/07/2024

Long-time collaborators Botond Roska and José-Alain Sahel win the Wolf Prize…

Botond Roska and José-Alain Sahel have been awarded the Wolf Prize in Medicine for their pioneering work on restoring vision to blind patients using optogenetic therapy.The Wolf Prize, considered one of the most prestigious international awards, recognizes outstanding achievements in various fields including medicine. Roska, Director at the Institute of Molecular and Clinical Ophthalmology Basel (IOB) and Professor at the University of Basel, and Sahel, Chair of Ophthalmology at the...
Nasdaq GlobeNewswire
05/07/2024

Going Global - Chime Biologics Embraces Innovation and Quality with Partners

Bing Chen, Vice President of International BD and Venture Fund at AstraZeneca mentioned that it was previously sufficient for innovative medicines to be a regional leader, but winning products now need to be best-in-class globally. By launching best-in-class products, Chinese pharmaceutical companies are more likely to attract additional global collaboration opportunities. Bing Chen, Vice President of International BD and Venture Fund at AstraZeneca mentioned that it was previously sufficient...
PR Newswire
05/07/2024

FDA approves Roche's Vabysmo prefilled syringe (PFS) for three leading causes of…

Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindnessDesigned to simplify administration, Vabysmo PFS provides retina specialists a ready-to-use option Vabysmo PFS will be available for people living with nAMD, DME and RVO Basel, 05 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the United States Food and Drug Administration (US FDA) has approved the Vabysmo® (faricimab) 6...
Nasdaq GlobeNewswire
05/07/2024

Medsenic, subsidiary of BioSenic SA, extends key patent to the United States

PRESS RELEASE – PRIVILEGED INFORMATION The developed Medsenic's composition-of-matter patent family does cover the therapeutic use of arsenic salts and metal ions through various routes of administration.Medsenic's enriched IP portfolio is aimed at protecting medications involving the combination of arsenic trioxide (ATO) and copper ions, which have demonstrated increased therapeutic potential for indications ranging from immune to cancer and to infectious diseases. ...
Nasdaq GlobeNewswire
05/07/2024

BK Virus Infection Market to Witness Surge in Growth During the Study Period…

Key Takeaways from the BK Virus Infection Market Report Key Takeaways from the BK Virus Infection Market Report Discover which therapies are expected to grab the major BK virus infection market share @ BK Virus Infection Market Report BK Virus Infection Overview The BK virus (BKV) is a member of the polyomavirus family and is highly prevalent in the general population, often remaining latent in the kidneys. Infection typically occurs in childhood, but it remains asymptomatic in...
PR Newswire
04/07/2024

Major shareholder announcement – BlackRock, Inc.

4 July 2024 Major shareholder announcement – BlackRock, Inc. ANNOUNCEMENT NO. 271 Major shareholder announcement – BlackRock, Inc. Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that BlackRock, Inc. has informed ChemoMetec A/S that BlackRock Investment Management (UK) Limited on 3 July 2024, increased its holding of voting rights attached to shares and voting rights in ChemoMetec A/S to above 10%, and that the holding thus exceeds the 10...
Nasdaq GlobeNewswire
04/07/2024

KFSH&RC Achieves Remarkable 98% Survival Rate in 400 Robotic Cardiac Surgeries

RIYADH, Saudi Arabia, July04, 2024(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was initiated in February 2019. Within its first year, the program performed 105 cardiac procedures. As of today, 400 robotic cardiac surgeries have been performed with a remarkable 98% survival rate.KFSH&RC is leading a healthcare revolution by harnessing robotics to transform...
Nasdaq GlobeNewswire
04/07/2024

Declaration of shares and voting rights - Valneva SE - June 30, 2024

VALNEVADeclaration of shares and voting rightsJune 30, 2024__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment B Declaration date: July 4, 2024 Number of sharescomposing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the...
Nasdaq GlobeNewswire
04/07/2024

Oxurion announces the results of the Extraordinary General Meeting (EGM) held on…

Oxurion announces the results of the Extraordinary General Meeting (EGM) held on 4 July 2024 and convenes a new EGM on 24 July 2024.Leuven, BELGIUM - 4 July 2024 – 6:00 PM CET,Oxurion NV(Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, informs its shareholders and the market that, at today's Extraordinary General Meeting, the attendance quorum required to deliberate and vote on the items on the agenda has not been reached, and that consequently, the...
Nasdaq GlobeNewswire
04/07/2024

Global Microscopy Market to Reach USD 10.6 Billion by 2029 driven by Healthcare…

Browse in-depth TOC on "Microscopy Market" Browse in-depth TOC on "Microscopy Market" 290 - Tables 62 - Figures 303 - Pages Key Players in the Microscopy Market: A Competitive Landscape The microscopy market features a competitive landscape dominated by major multinational corporations alongside significant contributions from SMEs and regional players. Key players includeCarl Zeiss AG( Germany ), Thermo Fisher Scientific (US), Danaher Corporation (US), EVIDENT ( Japan...
PR Newswire
04/07/2024

Digital Healthcare Market Size to reach $836.10 billion by 2031, growing at a…

Market Dynamics: Market Dynamics : The growth of digital healthcare market is driven by increasing adoption of telehealth and telemedicine. Telehealth allows remote consultation for the healthcare providers and patients which increases the convenience of treatment. During COVID-19 pandemic, telehealth witnessed exponential growth as it addressed the challenge of physical distancing. Moreover, growing usage of smartphones and tablets has fueled the demand for various healthcare apps for...
PR Newswire
04/07/2024

Sectra publishes Annual Report and Sustainability Report for 2023/2024

A summary of the financial year is also available on the website. The 2023/2024 financial year in brief summarizes the value we create for various stakeholders, highlights from our operations, and a selection of financial performance measures. A summary of the financial year is also available on the website.The 2023/2024 financial year in briefsummarizes the value we create for various stakeholders, highlights from our operations, and a selection of financial performance measures...
PR Newswire
04/07/2024

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase…

SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary endpoints of progression-free survival at primary analysis and overall survival at first interim analysisThe combination of tiragolumab plus Tecentriq and chemotherapy showed reduced efficacy compared to the comparator armSafety was consistent with previous studies, however we intend to halt the trial due to reduced efficacy compared to the comparator armBasel, 04 July 2024 - Roche...
Nasdaq GlobeNewswire
04/07/2024

BCG Unresponsive NMIBC Market to Register Sustainable Growth During the Study…

Key Takeaways from the BCG Unresponsive NMIBC Market Report Key Takeaways from the BCG Unresponsive NMIBC Market Report Discover which therapies are expected to grab the major BCG unresponsive NMIBC market share @ BCG Unresponsive NMIBC Market Report BCG Unresponsive NMIBC Overview BCG unresponsive non-muscle invasive bladder cancer (NMIBC) is a condition where bladder cancer does not adequately respond to Bacillus Calmette-Guérin (BCG) therapy, a common intravesical treatment...
PR Newswire
03/07/2024

Aker ASA: Streamlining Aker BioMarine, crystallizing value and re-investing in…

Based on Aker BioMarine's estimated excess cash following closing, Aker BioMarine is planning to pay an extraordinary dividend of NOK 35 to NOK 45 per share. Accordingly, Aker expects to receive gross cash proceeds between NOK 2.4 and NOK 3.1 billion, subject to final purchase price adjustments and the contemplated refinancing of Aker BioMarine. After an equity investment in Aker BioMarine Antarctic Holding II AS in the area of NOK 1.4 billion and a shareholder loan in the area of NOK 200…
PR Newswire
03/07/2024

Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews…

Annual Meeting Results Annual Meeting Results There was an exceptionally strong vote turnout at the 2023 Annual Meeting, with 961.7 million votes cast out of the total 1.2 billion shares outstanding as of the record date, comprising over 77% of all common and preferred shares outstanding. This vote turnout repeated the exceptional turnout at the 2022 Annual Meeting, where 841 million votes were cast comprising 78% of the total shares that were then outstanding. There were 5 Proposals...
PR Newswire
03/07/2024

Monthly information related to total number of voting rights and shares…

Article 223-16 of general regulation of French Autorité des Marchés FinanciersListing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM)Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut(1)voting rightsTotal of net(2)voting rights December 31, 20236 075 1056 226 9826 226 733January 31, 20246 075 1056 227 0026 226 753February 29, 20246 075 1056 226 951...
Nasdaq GlobeNewswire
03/07/2024
Altri  Comunicati